Clinical trial
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
NCT00131144 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00131144 |
|---|---|
| Title | Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy |
| Official title | A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo |
| Enrollment | 583 |
| Start date | Nov 1, 1999 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Aug 17, 2005 |
| Last update posted | Nov 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: